choose content

Choose content

Enter keywords to create a newsletter
create account

Create account

Enter your registration information
set preferences

Set preferences

Set up your newsletter name, delivery and time zone preferences
Hint: Enter different keywords to generate new results.

Now you can:

  1. Search the news index.
  2. Browse more than 1 million newsletters by category.
  3. Use preset newsletters:
    • Evista

Evista Newsletter
  • 7 Medications That May Interact With Green Tea 16 Oct 2025 02:37 GMT

    … tea. 3. Statins Statins, a type of drug used to treat … of green tea. 4. Evista (Raloxifene) Research has found … green tea while undergoing treatment with bortezomib. Check with … for more information and personalized medical advice. 6. Tacrolimus Tacrolimus …

  • Treatment Strategies for Osteoporosis 16 Sep 2025 16:58 GMT

    … The FDA has approved several drug therapies for the treatment … therapies owing to increased medication cost. Following discontinuation … Estrogen Receptor Modulators Raloxifene (Evista): Raloxifene is a selective … about calcitonin and clinical trials. Am J Med. …

  • Health Rounds: GLP-1 obesity drugs may boost low testosterone 16 Jul 2025 12:12 GMT

    … -boosting medications. During 18 months of treatment, the … DRUGS STILL YIELDS WEIGHT LOSS Popular GLP-1 anti-obesity medications … Medeiros said. OSTEOPOROSIS DRUGS CAN BENEFIT HIGH-RISK … Evista or Forteo. The others did not receive any osteoporosis drugs

  • People’s Pharmacy: Does this bone health drug help prevent breast cancer? 26 May 2025 13:20 GMT

    … PEOPLE’S PHARMACY: My doctor prescribed raloxifene when I … cancer. She believed this drug would block estrogen from … ! A. When raloxifene (Evista) was first introduced more … from other common osteoporosis drugs, bisphosphonates like alendronate (Fosamax …

  • Human medicines European public assessment report (EPAR): Evista, raloxifene, Date of authorisation: 05/08/1998, Revision: 31, Status: Authorised 01 Apr 2025 19:34 GMT

    Osteoporosis happens when not enough new bone grows to replace the bone that is naturally broken down. Gradually, the bones become thin and fragile, and more likely to break (fracture). Osteoporosis is more common in women after the menopause, when the …

  • Immediate Evista Review 2025: Scam or Legit Trading Platform? – Facts! 30 Jan 2025 06:28 GMT

    … Start Trading on Immediate Evista? The Immediate Evista crypto trading bot follows … can use the demo or trial mode with simulated funds to … payment methods available on Immediate Evista? Immediate Evista supports several secure payment …

  • Anthony Wallace of Bausch + Lomb talks about enVista Envy FDA approval 14 Oct 2024 21:56 GMT

    … + Lomb Corporation announced the FDA has granted approval to the … : Yeah, thanks, David. Well, eVista Envy offers a continuous range … little bit about the clinical trials and patient outcomes that … summer, we acquired Trukera Medical and its ScoutPro point-of …

  • Breast Cancer Screening and Treatment Update 18 Sep 2024 16:27 GMT

    drugs, primarily targeted therapies, have recently been FDA approved for treatment … , and medications. The … Relevant to Evista trial, raloxifene … Pharmaceutical Corp; March 2022. 29. Nerlynx (neratinib) product information. Los Angeles, CA: Puma Biotechnology, …

  • Athira Pharma Welcomes Dr. Javier San Martin as Chief Medical Officer 15 Apr 2024 14:03 GMT

    … “Javier’s decades of drug development experience will be … the first-in-human trial of ATH-1105 … better treatment options.” San Martin joins Athira from Arrowhead Pharmaceuticals, … trials to support the successful launch and medical affairs activities for Evista

  • Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer 15 Apr 2024 11:00 GMT

    … as a pioneer in drug development for patients with … the first-in-human trial of ATH-1105 in … treatment options.” Dr. San Martin joins Athira from Arrowhead Pharmaceuticals, … trials to support the successful launch and medical affairs activities for Evista

Satisfied with the content?

Continue to create your account.